Literature DB >> 7514558

Significance of specific antibody assay for genotyping of hepatitis C virus.

T Tanaka1, K Tsukiyama-Kohara, K Yamaguchi, S Yagi, S Tanaka, A Hasegawa, Y Ohta, N Hattori, M Kohara.   

Abstract

Group I and II hepatitis C virus genotypes were determined by a newly developed serological genotyping assay. This assay detected antibodies against group-specific recombinant proteins in the putative NS4 protein region (amino acid no. 1676-1760) by an enzyme-linked immunosorbent assay. This region of the hepatitis C virus peptide has many group-specific amino acids; fewer than 50% of these amino acids are identical between groups I and II. Genotypes determined by the serological genotyping assay were compared with those determined by a method in which the polymerase chain reaction was used in 91 chronic hepatitis patients. The group-specific polymerase chain reaction was performed within the genome region corresponding to the putative NS5 protein, where the group II hepatitis C virus genome is 57 nucleotides longer than that of group I. Among 91 chronic hepatitis C patients who had positive results in the second-generation hepatitis C virus antibody (core and NS3 region) assay, hepatitis C virus RNA was detected in 80 patients by polymerase chain reaction in the 5' untranslated region and in 78 patients by this group-specific polymerase chain reaction. As a result, in 76 of 91 patients (84%) genotypes determined by the serological genotyping assay showed complete agreement with those determined by the group-specific polymerase chain reaction, and none of the patients revealed a group opposite to that of hepatitis C virus genotype. The detection rate of the serological genotyping assay (89 of 91; 98%) was even higher than that of the polymerase chain reaction assay (78 of 91; 86%).(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7514558

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  45 in total

1.  Interferon inhibits progression of liver fibrosis and reduces the risk of hepatocarcinogenesis in patients with chronic hepatitis C: a retrospective multicenter analysis of 652 patients.

Authors:  Mitsuhiro Takimoto; Shogo Ohkoshi; Takafumi Ichida; Yasuo Takeda; Minoru Nomoto; Hitoshi Asakura; Akira Naito; Shigeki Mori; Kojiro Hata; Kentaro Igarashi; Hidenori Hara; Hironobu Ohta; Kenji Soga; Toshiaki Watanabe; Tomoteru Kamimura
Journal:  Dig Dis Sci       Date:  2002-01       Impact factor: 3.199

2.  Expression of type I interferon receptor in liver and peripheral blood mononuclear cells in chronic hepatitis C patients.

Authors:  Yuhki Yamaguchi; Keisuke Hino; Daisuke Fujiwara; Fenyu Ren; Yoshiharu Katoh; Yasuhiro Satoh; Kiwamu Okita
Journal:  Dig Dis Sci       Date:  2002-07       Impact factor: 3.199

3.  Prevalence of hepatitis C virus infection in Nanjing, southern China.

Authors:  K Suzuki; M Mizokami; K Cao; X S Wu; R R Wu; A Hata; M Sasaki; Z X Fang; L Y Zhang; J Y Lau; S Iino
Journal:  Eur J Epidemiol       Date:  1997-07       Impact factor: 8.082

4.  Genome-wide association study identifies a susceptibility locus for HCV-induced hepatocellular carcinoma.

Authors:  Vinod Kumar; Naoya Kato; Yuji Urabe; Atsushi Takahashi; Ryosuke Muroyama; Naoya Hosono; Motoyuki Otsuka; Ryosuke Tateishi; Masao Omata; Hidewaki Nakagawa; Kazuhiko Koike; Naoyuki Kamatani; Michiaki Kubo; Yusuke Nakamura; Koichi Matsuda
Journal:  Nat Genet       Date:  2011-04-17       Impact factor: 38.330

5.  Quantification of serum hepatitis C virus core protein level in patients chronically infected with different hepatitis C virus genotypes.

Authors:  E Orito; M Mizokami; T Tanaka; J Y Lau; K Suzuki; M Yamauchi; Y Ohta; A Hasegawa; S Tanaka; M Kohara
Journal:  Gut       Date:  1996-12       Impact factor: 23.059

Review 6.  Hepatitis C virus: molecular biology and genetic variability.

Authors:  C Bréchot
Journal:  Dig Dis Sci       Date:  1996-12       Impact factor: 3.199

7.  Hepatitis C virus (HCV) subtype prevalence in Chiang Mai, Thailand, and identification of novel subtypes of HCV major type 6.

Authors:  H Doi; C Apichartpiyakul; K I Ohba; M Mizokami; H Hotta
Journal:  J Clin Microbiol       Date:  1996-03       Impact factor: 5.948

8.  Increase of chemokine interferon-inducible protein-10 (IP-10) in the serum of patients with autoimmune liver diseases and increase of its mRNA expression in hepatocytes.

Authors:  K Nishioji; T Okanoue; Y Itoh; S Narumi; M Sakamoto; H Nakamura; A Morita; K Kashima
Journal:  Clin Exp Immunol       Date:  2001-02       Impact factor: 4.330

9.  Serological determination of hepatitis C virus genotype: comparison with a standardized genotyping assay.

Authors:  J M Pawlotsky; L Prescott; P Simmonds; C Pellet; P Laurent-Puig; C Labonne; F Darthuy; J Remire; J Duval; C Buffet; J P Etienne; D Dhumeaux; E Dussaix
Journal:  J Clin Microbiol       Date:  1997-07       Impact factor: 5.948

10.  Significance of prior hepatitis B virus infection in the development of hepatocellular carcinoma in patients with chronic hepatitis C.

Authors:  Fumio Imazeki; Osamu Yokosuka; Kenichi Fukai; Akira Hiraide; Hiromitsu Saisho
Journal:  Dig Dis Sci       Date:  2003-09       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.